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Abstract
The oligosaccharides 2-fucosyllactose and 3-fucosyllactose are major constituents of human breast milk but are not found in mouse milk.
Milk oligosaccharides have a prebiotic action, thus affecting the colonisation of the infant intestine by microbiota. To determine the specific
effect of fucosyllactose exposure on intestinal microbiota in mice, in the present study, we orally supplemented newborn mice with pure
2-fucosyllactose and 3-fucosyllactose. Exposure to 2-fucosyllactose and 3-fucosyllactose increased the levels of bacteria of the Porphyro-
monadaceae family in the intestinal gut, more precisely members of the genus Barnesiella as analysed by 16S pyrosequencing. The ability
of Barnesiella to utilise fucosyllactose as energy source was confirmed in bacterial cultures. Whereas B. intestinihominis and B. viscericola
did not grow on fucose alone, they proliferated in the presence of 2-fucosyllactose and 3-fucosyllactose following the secretion of linkage-
specific fucosidase enzymes that liberated lactose. The change in the composition of intestinal microbiota mediated by fucosyllactose
supplementation affected the susceptibility of mice to dextran sulphate sodium-induced colitis, as indicated by increased resistance of
mice subjected to 2-fucosyllactose supplementation for 6 weeks. The present study underlines the ability of specific milk oligosaccharides
to change the composition of intestinal microbiota and thereby to shape an intestinal milieu resilient to inflammatory diseases.
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Oligosaccharides are major constituents of human breast milk.
Milk oligosaccharides are built up by multiple glycosyl-
transferases expressed in the secretory mammary gland by
extending the lactose core, thereby forming about 200 various
structures(1). Milk oligosaccharides do not deliver energy to
the newborn as the human gut lacks the glycosidase machinery
required to break down these complex carbohydrates. Rather,
milk oligosaccharides have a prebiotic action providing a
nutrient milieu for the microbial colonisation of the intestine(2),
thereby influencing the development of the mucosal immune
system of breast-fed infants(3). Milk oligosaccharides shape
the intestinal flora by providing fermentable carbohydrates to
selected bacterial groups and by acting as soluble receptors
preventing the adhesion of other bacteria(4–6). The remarkable
diversity of milk oligosaccharides hampers the attribution of
specific functions to individual structures. To date, only a few
studies have unravelled the biological impact of singlemilk oligo-
saccharides. For example, lacto-N-fucopentaose III was shown to
induce the production of IL-10 and PGE2 in spleen cells(7).
Disialyllacto-N-tetraose was shown to lower the incidence of
necrotising enterocolitis in rats(8). Finally, 3-sialyllactose was
shown to influence the intestinal abundance of clostridial cluster
IV bacteria in mice and hence their susceptibility to dextran
sulphate sodium (DSS)-induced colitis(9).
Fucosyllactose is a major constituent of human milk oligosac-
charides(10), whereas only trace amounts are found in mouse
milk(11). Fucosyllactose occurs as Fuc(a1–2)Gal(b1–4)Glc, also
called 2-fucosyllactose (2-FL), and Fuc(a1–3)(Gal(b1–4))Glc,
called 3-fucosyllactose (3-FL). 2-FL is similar to the blood group
H-antigen and 3-FL to the Lewis-X antigen found on glyco-
proteins and glycolipids(12). 2-FL accounts for 20% of total
human milk oligosaccharides and 3-FL for less than 1%(13). The
abundance of 2-FL in human milk suggests an evolutionary
pressure pertaining to the development of beneficial effects on
infant physiology. Along the way, ex vivo and in vivo studies
have shown that 2-FL inhibits the mucosal attachment and
intestinal colonisation of Campylobacter jejuni, hence lowering
the incidence of diarrhoea(14,15). Fucosyllactose also acts as
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a protected source of lactose for bacteria expressing fucosidase
enzymes, such as bifidobacteria and Bacteroides, whereas
Escherichia coli and Clostridium perfringens cannot utilise 2-FL
as nutrient(16).
The potential of specific oligosaccharides to influence
intestinal colonisation by commensal microbiota in vivo is not
known. To address the potential contribution of fucosyllactose
to shaping of the distribution of intestinal microbiota, we supple-
mented newborn mice with 2-FL and 3-FL, which are naturally
not found in mouse milk. The lack of fucosylated oligo-
saccharides in mouse milk may decrease the selection of
fucosidase-expressing bacteria. The exposure of infant mice to
soluble 2-FL and 3-FL may also impair the adhesion of bacteria
to fucosylated glycans in the gastrointestinal mucosa or interfere
with the bacterial regulation of host-derived fucosylated glycans
through interaction with bacterial carbohydrate sensors, such as
the FucR of Bacteroides thetaiotaomicron (17). Previous exper-
iments have demonstrated the effect of the milk oligosaccharide
3-sialyllactose on microbial composition as well as on the extent
of chemically induced intestinal inflammation(9). Beyond the
effect on intestinal microbial colonisation, the question as to
whether fucosyllactose supplementation has an impact on the
severity of an inflammatory disease was addressed using the
DSS-induced colitis model.
Experimental methods
Fucosyllactose supplementation in mice
Newborn C57BL/6 mice were fed orally with 500mmol/l of
2-FL and 3-FL (Glycom) daily from day 1 to day 20 after birth
starting with 5ml, increasing by 2·5ml every 2–3d reaching a
daily amount of 25ml on day 20. Sterile water was given as
negative control. For supplementation after weaning, 2-FL
and 3-FL were added to drinking-water (3·3mmol/l) from day
21 to day 45. Fresh faeces were collected on day 21 and
day 45 and immediately stored at 2808C until further analysis.
Dextran sulphate sodium-induced colitis
From day 45 postpartum, 2·75% (w/v) of DSS (catalogue no.
0216011090; MP Biomedicals) was added to drinking-water for
5 d followed by provision of normal drinking-water for 2 d until
mice were killed. Body weight was monitored daily. Mice in
which body weight decreased to 85% of the initial body
weight were killed immediately. Experiments were carried
out in compliance with the Swiss Animal Protection Ordinance
and approved by the local veterinary authority (Kantonales
Veterina¨ramt Zu¨rich, Switzerland). Faecal calprotectin
concentrations were determined by ELISA (Immunodiagnostik)
following the manufacturer’s protocol.
Bacterial DNA extraction and amplification
DNA was isolated from faecal samples using the QIAamp DNA
Stool Mini Kit (catalogue no. 51 504; Qiagen) according to the
manufacturer’s instructions. To detect cells that are difficult to
lyse, the temperature at which faecal samples were incubated
in lysis buffer was increased to 958C. The DNA concentrations
of extracts were measured using NanoDrop (Witec AG).
Aliquots of 100 ng of extracted DNA were subjected to PCR
using the 16S rDNA universal heteroduplex analysis (HDA)
primers HDA1-GC 50-CGCCCGGGGCGCGCCCCGGGCGGG-
GCGGGGGCACGGGGGGACTCCTACGGGAGGCAGCAGT-30
and HDA2 50-TTACCGCGGCTGCTGGCA-30 at 568C for strand
annealing. Initial denaturation at 948C for 4 min was followed
by thirty cycles of 30 s at 948C, 30 s at 568C and 1 min at 728C.
The quality of PCR products was verified by agarose gel
electrophoresis.
Denaturing gradient gel electrophoresis and species
identification
Amplified 16S rDNA fragments were separated by denaturing
gradient gel electrophoresis (DGGE) using an INGENYphorU
(Ingeny International BV) system equipped with 6 %
polyacrylamide gels with a denaturant in the range of
30–55 %, where 100 % denaturant is equivalent to 7 M-urea
and 40 % formamide. Electrophoresis was carried out at 130 V
for 4·5 h at 608C. Polyacrylamide gels were stained with
GelRede nucleic acid stain (catalogue no. 41 003; Biotium) for
45min, destained in ultrapure water and viewed under UV
light. Bands of interest were excised from gels and lysed in
ultrapure water. Extracted DNA was reamplified using the same
primers and PCR conditions. To purify the bacterial DNA, PCR
products were reloaded on a denaturant gradient gel followed
by excision and lysis of selected bands. DNA samples recovered
from lysed bands of the second DGGE were reamplified by
PCR before purification using the QIAquick PCR Purification
Kit (catalogue no. 28 104; Qiagen) and sequenced (Microsynth
AG). Species identification was done using the Ribosomal
Microbiome Database Project Classifier tool(18).
Pyrosequencing and data processing
The V5–V6 region of 16S rRNA from faecal DNA samples was
amplified using the primers 784F 50-AGGATTAGATACCCT-
GGTA-30 and 1061R 50-CRRCACGAGCTGACGAC-30 3640(19).
Amplicons were pyrosequenced using a Roche 454 GS-FLX
system (DNAVision). Sequences of at least 240 nucleotides
and containing no more than two undetermined bases were
retained for taxonomic assignment. The QIIME software(20)
was used for chimera check and the Greengenes database(21)
was used for classification. Bacterial diversity was determined
at the phylum, family and genus levels. Sequences were aligned
to the 16S rRNA of B. intestinihominis and B. viscericola
with BLASTN 2.2.27þ (22). The GenBank accession numbers
for the 16S rDNA sequences of B. intestinihominis and
B. viscericola are AB267809.1 and AB370251.1, respectively.
Bacterial culture
Strains of B. viscericola and B. intestinihominis were obtained
from Leibniz-Institut, Deutsche Sammlung von Mikroorganis-
men und Zellkulturen GmbH. Cell morphology was inspected
visually by microscopy (DM1000 10 £ /20 microscope; Leica).
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Substrate utilisation was determined by adding sterilised,
O2-free sugar solutions of glucose, lactose, fucose, 2-FL or
3-FL at a final concentration of 2·44 g/l to yeast extract, casitone,
fatty acid (YCFA) medium(23). YCFA medium was dispensed in
8 ml aliquots in Hungate tubes sealed with butyl rubber septa.
SCFA were added to the medium at the final concentrations
of 32·4 mmol acetate/l, 4·7 mmol butyrate/l, 8·7 mmol
propionate/l, 1 mmol n-valeric acid/l and 1·2 mmol isobutyric
acid/l. YCFA medium was prepared and maintained anaero-
bically using CO2. Inoculated tubes were incubated at 378C.
Growth was measured spectrophotometrically at 600 nm.
Statistical analysis
Data are presented as means and standard deviations, unless
otherwise indicated. Comparisons of means were made with
t test or one-way ANOVA using SPSS 20. P values lower than
0·05 were considered significant.
Results
Microbial variation after 3 and 6 weeks of
supplementation
To determine whether early exposure to exogenous fucosyllac-
tose influenced intestinal microbial, we first compared three
supplementation regimens. Mice were fed daily with 2-FL or
3-FL for 3 weeks from birth to weaning, for 3 weeks after wean-
ing or for 6 weeks from birth (Fig. 1). The latter protocol was
referred to as long-term supplementation. Before weaning,
2-FL and 3-FL were given orally in addition to the natural feed-
ing of the pups through maternal milk. Microbiological diversity
in faecal samples was first examined by DGGE of amplified
bacterial 16S rDNA fragments. By the time of weaning, the
DGGE profiles obtained for the 2-FL- and 3-FL-supplemented
mice and control mice were very similar with only a few DNA
bands specifically being found in single supplementation
groups. The main difference was represented by a band corre-
sponding to bacteria of the Lachnospiraceae family observed in
the 2-FL-supplemented mice (data not shown). DGGE profiles
obtained from DNA samples isolated from mice at 6 weeks of
age exhibited more pronounced changes as exemplified
by prominent bands representing members of the Porphyromo-
nadaceae family (Fig. 2). The increase in the bacterial numbers
of the Porphyromonadaceae family was strongest in mice
supplemented with 2-FL for 6 weeks, whereas mice
supplemented with 2-FL and 3-FL for 3 weeks after weaning
also exhibited an increase in bacterial numbers, yet to a lesser
extent than mice exposed to 2-FL or 3-FL for the whole study
period. The DGGE band corresponding to the bacteria of
the Porphyromonadaceae family was weaker in mice
supplemented with 2-FL than in those supplemented with
3-FL for 3 weeks after weaning. Because of the limited sensitivity
M 3–6 weeks 0–6 weeks 3–6 weeks 0–6 weeks
3-FL2-FL
C MC M
Fig. 2. Denaturing gradient gel electrophoresis profiles of bacterial 16S rDNA isolated from faecal samples at the age of 6 weeks. Variations in bacterial compo-
sition in the 2-fucosyllactose (2-FL)-supplemented, 3-fucosyllactose (3-FL)-supplemented and control mice (n 8) were compared. The duration of 2-FL or 3-FL
supplementation is indicated as 3–6 weeks (n 8 and 9, respectively) or 0–6 weeks (n 9 and 7, respectively). Each lane represents DNA of faecal bacteria from
one mouse. The arrow heads at the left and right point to a band corresponding to a member of the Porphyromonadaceae family. M, marker; C, control.
0 2
1·2 1·8 2·4 3·1 3·7 4·3 4·9 5·5 6·1 7·2
Days after birth
Faecal
analysis
Weaning,
faecal analysis
4 6 8 10 12
Feeding of 2-FL or 3-FL (mg/d)
2-FL or 3-FL in
drinking-
water DSS (2·75%)
14 16 18 20 22 44 46 48 50
Fig. 1. Fucosyllactose (2-FL or 3-FL) supplementation protocol. Fucosyllactose was fed orally until weaning at increasing daily amounts. Fucosyllactose
supplementation after weaning was administered through drinking-water. Average daily consumption of 4·5 ml drinking-water per d in one mouse resulted in a
daily intake of 7·2 mg fucosyllactose. Dextran sulphate sodium (DSS, 2·75 %) was added to drinking-water from day 45 to day 50.
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of DGGE to quantify microbial diversity, we also analysed the
microbial composition of DNA samples using high-throughput
sequencing.
Each sample was analysed at coverage ranging from 6898 to
16 171 16S rDNA sequences. The grouping of sequences at the
level of bacterial families confirmed the results obtained by
DGGE. Mice supplemented with 2-FL from birth for 3 weeks
had increased levels of bacteria of the Lachnospiraceae family
(Fig. 3(a)), whereas those of bacteria of other families did not
vary significantly after exposure of mice to 2-FL and 3-FL
(Table 1). Reciprocally, the abundance of bacteria of the
Alcaligenaceae family strongly decreased in the 2-FL-
supplemented mice, while that of bacteria of the remaining
families remained unchanged in the 3-FL-supplemented mice.
The dominant bacterial families identified at 3 weeks of age
were Porphyromonadaceae and Bacteroidaceae, which
accounted for, respectively, 39 and 16 % of sequence coverage
in the control mice. After weaning at 3 weeks of age, the
transition from breast milk to solid chow led to several
adjustments in the distribution of intestinal microbiota in the
control and fucosyllactose-supplemented mice (Table 1). The
bacteria of the Porphyromonadaceae family remained
dominant in all mouse groups at 6 weeks of age, yet with a
sharp increase in numbers in the 2-FL- and 3-FL-supplemented
mice (Fig. 3(b)). The analysis of bacterial sequences at the genus
level revealed that Barnesiella accounted for the observed
increase in the bacterial numbers of the Porphyromonadaceae
family (Table 2). At the age of 6 weeks, varying levels of
Barnesiella were observed in the three mouse groups
(Fig. 3(c)). Whereas Barnesiella summed up to 58·3 % of the
identified genera in the 2-FL-supplemented mice, Barnesiella
summed up to, respectively, 47·0 and 39·6 % of the genera in
the 3-FL-supplemented mice and control mice.
Fucosyllactose utilisation by Barnesiella
To date, two species of Barnesiella, namely B. viscericola
isolated from chicken caecum and B. intestinihominis from
human faeces, have been characterised and cultivated(24,25).
The Barnesiella sequences obtained in the present study
exhibited up to 93% identity with the reference 16S rDNA
sequence of B. intestinihominis and B. viscericola. The
enrichment of Barnesiella found in the fucosyllactose-
supplemented mice suggested that these bacteria are able to
utilise fucosyllactose as carbon source. To address this
question, we monitored the growth of B. viscericola and
B. intestinihominis in vitro in culture medium containing
glucose, lactose, fucose, 2-FL or 3-FL as the sole energy source.
As expected, both Barnesiella species grew in the medium
containing glucose and lactose (Fig. 4(a)–(d)). By contrast,
Barnesiella failed to grow in the presence of fucose, indicating
that these bacteria cannot utilise this deoxyhexose as carbon
source (Fig. 4(e) and (f)). The addition of either 2-FL or 3-FL to
the growth medium revealed the differential utilisation of both
forms of fucosyllactose by B. viscericola and B. intestinihominis.
Whereas B. intestinihominis was able to grow in the 2-FL-
containing medium but not in the 3-FL-containing medium
(Fig. 4(g) and (i)), the reverse phenotype was observed for
B. viscericola, which grew in the presence of 3-FL but not in
the presence of 2-FL (Fig. 4(h) and (j)). Noteworthily, the
growth of B. intestinihominis in the presence of 2-FL was
delayed, suggesting that the utilisation of the oligosaccharide as
energy source required the expression of a putative fucosidase.
During the growth experiments, the cell morphology of
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Fig. 3. Association between individual bacterial species and fucosyllactose
supplementation. Relative abundances of the Lachnospiraceae family (a),
the Porphyromonadaceae family (b) and the Barnesiella genus (c) were
determined in the faecal samples of the long-term supplemented and control
mice at 3 and 6 weeks of age by pyrosequencing. Values are means
(n 5 mice per group), with standard deviations represented by vertical bars.
* Mean value was significantly different from that of the control mice
(P,0·05; t test). † Mean value was significantly different from that of the 3-
FL-supplemented mice (P,0·05; t test). ‡ Mean value was significantly differ-
ent from that of the control mice (P,0·1; trend; t test). § Mean value was
significantly different from that of the 3-FL-supplemented mice (P,0·1; trend;
t test). 2-FL, 2-fucosyllactose; 3-FL, 3-fucosyllactose; C, control.
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Table 1. Relative abundance of bacterial families in 2-fucosyllactose (2-FL)- or 3-fucosyllactose (3-FL)-supplemented and control mice at the age of
3 and 6 weeks
(Mean values and standard deviations; n 5 mice per group)*
After 3 weeks After 6 weeks
2-FL 3-FL Control 2-FL 3-FL Control
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Total reads† (n) 10 377–12 327 6898–12 181 11 046–16 171 9463–13 551 2624–11 960 3414–6888
Sequence assignment (%) 37–47 30–44 28–48 33–40 30–41 23–54
Alcaligenaceae 0·5 0·4 6·2 4·1 6·9 9·4 2·1 0·5 2·2 2·2 1·6 1·0
Anaeroplasmataceae 0·0 0·1 2·1 2·6 2·7 3·0 3·2 1·5 0·9 0·7 3·4 3·4
Bacteroidaceae 27·1 13·7 24·4 16·4 15·6 9·5 5·2 1·8 7·3 2·0 8·4 10·1
Coriobacteriaceae 0·1 0·1 0·3 0·2 0·1 0·2 0·1 0·0 0·2 0·1 0·1 0·1
Deferribacteraceae 0·0 0·0 0·2 0·3 0·3 0·3 0·1 0·1 0·0 0·0 0·6 0·7
Erysipelotrichaceae 0·1 0·1 1·8 1·9 2·2 2·8 0·7 0·3 2·1 1·2 0·9 1·3
Helicobacteraceae 1·7 1·1 2·1 1·9 5·1 3·8 2·7 1·0 2·7 0·9 2·4 1·2
Incertae Sedis XIV 0·2 0·4 0·1 0·1 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0
Lachnospiraceae 17·4 8·9 5·5 1·4 4·7 3·4 3·9 1·0 5·1 2·5 9·4 6·2
Lactobacillaceae 2·2 1·0 4·7 4·4 3·2 2·3 1·3 1·5 1·1 1·4 0·6 0·9
Mycoplasmataceae 0·7 0·7 0·2 0·2 0·7 0·7 0·4 0·1 0·5 0·4 0·1 0·1
Porphyromonadaceae 35·4 9·0 34·8 9·9 38·8 8·7 61·8 3·8 54·8 4·8 37·6 14·9
Prevotellaceae 5·1 3·0 3·2 1·0 4·4 3·5 3·7 0·8 3·7 0·8 4·9 3·2
Rikenellaceae 5·4 2·1 7·0 4·7 9·4 5·6 6·3 0·8 6·2 2·9 6·3 2·1
Ruminococcaceae 3·8 1·7 7·1 4·0 5·0 2·2 8·4 1·6 13·1 3·8 23·7 21·1
Verrucomicrobiaceae 0·0 0·0 0·0 0·0 0·7 1·4 0·0 0·0 0·0 0·0 0·0 0·0
* Only families that are present with a mean value of more than 0·2 % in at least one group are displayed.
† Number of read sequences passing quality control.
Table 2. Relative abundance of bacterial genera in 2-fucosyllactose (2-FL)- or 3-fucosyllactose (3-FL)-supplemented and control mice at the age of
3 and 6 weeks
(Mean values and standard deviations; n 5 mice per group)*
After 3 weeks After 6 weeks
2-FL 3-FL Control 2-FL 3-FL Control
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Total reads† (n) 10 377–12 327 6898–12 181 11 046–16 171 9463–13 551 2624–11 960 3414–6888
Sequence assignment (%) 21–30 20–30 20–38 22–28 20–26 14–25
Akkermansia 0·0 0·0 0·1 0·0 0·8 1·7 0·0 0·0 0·0 0·1 0·0 0·0
Alistipes 8·0 3·7 8·4 5·8 10·8 7·5 8·5 0·9 7·6 3·1 10·5 1·8
Allobaculum 0·0 0·0 0·6 0·5 0·0 0·0 0·7 0·5 1·6 1·2 0·4 0·8
Anaeroplasma 0·1 0·1 3·1 3·8 3·6 4·0 4·7 2·1 1·3 1·2 6·6 5·6
Bacteroides 42·5 20·9 34·1 21·7 20·2 11·1 7·7 2·7 11·2 3·5 15·0 15·5
Barnesiella 17·4 8·0 16·3 7·3 25·4 5·4 58·3 5·4 47·0 10·2 39·6 16·1
Blautia 0·4 0·7 0·1 0·2 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0
Butyricicoccus 0·0 0·0 0·0 0·0 0·0 0·0 0·2 0·2 0·0 0·1 0·4 0·6
Coprobacillus 0·1 0·1 0·7 0·9 1·4 1·5 0·2 0·1 0·5 0·4 0·4 0·4
Helicobacter 2·5 1·7 2·8 2·4 6·1 4·8 3·7 1·4 3·8 1·3 4·4 3·5
Lactobacillus 3·6 2·1 7·0 6·9 4·4 3·2 1·9 2·1 1·8 2·4 1·1 1·5
Marvinbryantia 0·0 0·0 0·1 0·1 0·0 0·0 0·1 0·0 0·1 0·1 0·3 0·2
Mucispirillum 0·0 0·0 0·4 0·4 0·4 0·4 0·1 0·1 0·0 0·1 1·7 2·2
Odoribacter 0·2 0·1 0·0 0·0 0·8 0·8 0·6 0·2 0·0 0·0 0·9 0·5
Oscillibacter 2·3 1·1 1·1 1·0 1·1 0·9 1·8 0·4 1·9 1·1 3·6 2·6
Parabacteroides 13·9 6·4 13·1 4·9 11·4 6·5 4·1 2·2 13·3 7·5 5·0 6·4
Paraprevotella 0·0 0·0 0·0 0·0 0·3 0·6 0·0 0·0 0·0 0·0 0·0 0·0
Parasutterella 0·4 0·4 6·3 4·2 7·3 10·0 1·6 0·3 2·7 2·9 2·7 1·6
Prevotella 6·1 3·4 3·6 1·1 3·9 2·3 4·2 0·9 4·4 1·0 5·3 1·9
Roseburia 0·1 0·1 0·7 0·6 0·1 0·2 0·1 0·1 0·3 0·2 0·0 0·1
TM7 genera incertae sedis 0·4 0·4 0·5 0·4 0·1 0·2 0·5 0·4 0·8 0·6 0·4 0·4
Ureaplasma 1·1 1·2 0·3 0·3 0·9 0·9 0·6 0·2 0·7 0·6 0·2 0·2
Xylanibacter 0·4 0·2 0·3 0·3 0·2 0·1 0·3 0·2 0·3 0·1 0·9 0·7
* Only genera that are present with a mean value of more than 0·2 % in at least one group are displayed.
† Number of read sequences passing quality control.
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Barnesiella was monitored by Gram staining to confirm the
purity of the two strains in culture (Fig. S1, available online).
Dextran sulphate sodium-induced colitis in the
fucosyllactose-supplemented mice
We finally investigated whether the changes in intestinal
microbiota mediated by 2-FL and 3-FL supplementation
affected the susceptibility of mice to local inflammation.
Therefore, we treated mice with DSS to induce acute colitis.
Loss of body weight was assessed to monitor the severity of
the response to DSS in the different mouse groups.
Supplementation of 2-FL and 3-FL during lactation or for
3 weeks after weaning had no influence on the body-weight
loss induced by DSS uptake (Fig. 5(a) and (b)). By contrast,
2-FL supplementation for 6 weeks decreased the severity of
DSS-induced colitis (Fig. 5(c)). Similarly, long-term 3-FL
supplementation led to reduced weight loss, although to a
lesser extent than 2-FL supplementation. The difference
between the supplementation groups was observed in male
mice, which responded more strongly to DSS than females
(Fig. 5(d)). Accordingly, male mice exposed to 2-FL and
3-FL maintained higher body weight values than the control
mice, indicating a protective effect of the oligosaccharides
towards exposure to DSS. The reduced severity of colitis
observed in the 2-FL-supplemented mice was confirmed by
measuring calprotectin concentrations in the faecal samples
of treated mice (Fig. 5(e)). Calprotectin is secreted by
infiltrating neutrophils and monocytes and is broadly used
as a marker of intestinal inflammation(26,27). The correlation
of DSS sensitivity with the levels of Barnesiella bacteria in
the intestine of the 2-FL-supplemented mice suggests that
this bacterial genus may confer anti-inflammatory properties
in the context of DSS challenge.
Discussion
The present study demonstrated that the exposure of young
mice to the fucosyllactose isoforms 2-FL and 3-FL, which are
absent in mouse milk, affects the composition of intestinal
microbiota. Specifically, the levels of Barnesiella increased
after 6 weeks of fucosyllactose supplementation. Barnesiella,
a genus of the family of Porphyromonadaceae, order
Bacteroidales, was one of the most abundant genera detected
in mouse intestine. Already by 3 weeks of age, it accounted for
up to 25 % of total intestinal microbiota in mice. At the age of
6 weeks, this proportion increased to about 40 % in the control
mice, whereas the abundance of Barnesiella rose close to 60 %
in the 2-FL-supplemented mice. The dominance of these
bacterial families in the murine gut was confirmed by Bailey
et al.(28), who assigned approximately 30 % of the identified
sequences to each of these two families. Wohlgemuth
et al.(29) also identified Porphyromonadaceae as the most
abundant family with 37 % of sequences, while they assigned
9 % of sequences to Bacteroidaceae. Members of the order
Bacteroidales contribute to carbohydrate degradation and by
competition prevent the colonisation of the intestine by
pathogenic bacteria(30). Specifically, Barnesiella bacteria are
able to eliminate and protect against the intestinal dominance
of antibiotic-resistant pathogenic bacteria that can be observed
in hospitalised patients(31). The abundance of Barnesiella
correlates with the amount of several immunoregulatory
cells. The higher the levels of Barnesiella in the colon, the
more marginal zone B cells and invariant natural killer T cells
enumerated in the spleen and liver(32). Furthermore, a direct
association between a change in microbial composition in
favour of Barnesiella and the resistance to arthritis has been
demonstrated in mice(33). Arthritis-resistant mice are
characterised by microbiota enriched with Barnesiella,
Bifidobacterium and Parabacteroides spp., with Barnesiella
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Fig. 4. Selective growth of Barnesiella intestinihominis (a, c, e, g, i) and
B. viscericola (b, d, f, h, j) with different sugar substrates. The two
Barnesiella strains were incubated in yeast extract, casitone, fatty acid
medium supplemented with (a, b) glucose, (c, d) lactose, (e, f) fucose, (g, h)
2-fucosyllactose (2-FL) or (i, j) 3-fucosyllactose (3-FL). Proliferation was
measured spectrophotometrically at 600 nm. Values are means of two
experiments carried out in triplicate, with standard deviations represented by
vertical bars. OD, optical density.
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being the most abundant genus. In the development of colitis
in IL-102/2 mice, higher levels of a Barnesiella phylotype
correlated with lower activity levels of the disease(34). In the
last few years, many new sequences have been isolated
from human and animal intestine and assigned to the genus
Barnesiella (35,36). It still remains to be determined how the
abundance of Barnesiella is linked to inflammatory diseases
of the gastrointestinal tract.
As demonstrated in the present study, B. intestinihominis
and B. viscericola can utilise fucosyllactose as energy source.
This phenotype was contingent on the expression of linkage-
specific fucosidases based on the respective specific
utilisation of 2-FL and 3-FL by both Barnesiella species.
B. intestinihominis had been previously tested negative(24)
and B. viscericola positive for a-fucosidase(25), although the
linkage specificity of this activity was not addressed. The
expression of glycosidases able to cleave carbohydrates
capping lactose brings a selective advantage to bacteria
competing for energy in the densely populated gastro-
intestinal environment. The gut of breast-fed newborns is
enriched with Bacteroides and Bifidobacterium species that
possess a-fucosidase and a-sialidase activity(2,37–39). As
a-fucosidase and a-sialidase conduct the first step of milk
oligosaccharide metabolisation by removing terminal
monosaccharides, the expression of these two enzymes
leads to the successful intestinal establishment of species
such as Bifidobacterium infantis, Bifidobacterium bifidum,
Bacteroides fragilis and Bacteroides thetaiotaomicron
in breast-fed infants(37,40,41). Bacteria that do not exhibit
a-fucosidase or a-sialidase activity, e.g. Bifidobacterium
adolescentis and Bifidobacterium animalis, are not able to
grow solely on milk oligosaccharides and, therefore, do not
belong to the typical infant-associated microbiota(42). Little is
known about the carbohydrate-metabolising activity of
Barnesiella, but the feeding of obese mice with oligofructose
has been shown to increase the abundance of Barnesiella
by 26%(43).
As has been shown recently, specific milk oligosaccharides
have a significant impact on the severity of intestinal
inflammation(9). This effect seems to be microbiota mediated.
The differential susceptibility of mice to DSS-induced colitis
indicated that the shift in microbial composition elicited by
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Fig. 5. Susceptibility of the fucosyllactose-supplemented mice to acute colitis. Acute colitis was induced in the fucosyllactose-supplemented and control mice by
dextran sulphate sodium (DSS) treatment at the age of 6 weeks. Treatment with DSS in drinking-water was started on day 0. On day 5, treatment was ended by
changing to normal drinking-water. Loss of body weight was monitored during DSS treatment and two subsequent days in mice supplemented for (a) 3 weeks
until weaning, (b) 3 weeks after weaning and (c) 6 weeks (long-term supplementation). Values are means, with standard deviations represented by vertical bars.
(a, c) Pooled data from two independent experiments. (a) Because of low body weight, two mice supplemented with 3-fucosyllactose (3-FL) for 3 weeks were
killed by day 6 of DSS treatment. 2-FL , 2-fucosyllactose ((a) n 15, (b) n 8 and (c) n 18); 3-FL ((a) n 12–14, (b) n 9 and (c) n 13); C , control ((a) n 11,
(b) n 8 and (c) n 16). Mean value was significantly different from that of the control mice: *P,0·05, **P,0·001 (t test). (d) Loss of body weight in male and female
mice was compared on day 7 after the start of DSS treatment in the long-term supplemented group. (e) Calprotectin concentrations in the faeces of the 2-FL- and
3-FL-supplemented mice (for 6 weeks) and control mice analysed on day 7 of DSS treatment. Values are means from pooled data of two independent
experiments (males n 8 (2-FL), 9 (3-FL) and 9 (control) and females n 10 (2-FL), 4 (3-FL) and 7 (control)), with standard errors represented by vertical bars. Mean
value was significantly different from that of the control mice: *P,0·05, ****P,0·0001 (one-way ANOVA). † Mean value was significantly different from that of the
3-FL-supplemented mice (P,0·05; one-way ANOVA).
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2-FL supplementation had a significant biological impact on the
health of the treated animals. The decreased susceptibility to
DSS correlated with the levels of Barnesiella in the 2-FL-sup-
plemented mice, suggesting that Barnesiella could render the
intestinal milieu less prone to inflammation. The protective
effect of 2-FL supplementation was strongest in male mice,
whereas the long-term supplemented female mice did not
differ significantly in their reaction to DSS from female control
mice. Future experiments will examine whether the distribution
of specific bacterial groups such as Barnesiella presents sex
differences after fucosyllactose supplementation. Along this
line, differences in the intestinal microbiome of male v.
female mice were reported in the context of an arthritis suscep-
tibility study, in which male mice had higher levels of B. viscer-
icola than female mice(33).
The present study demonstrated that supplementation with
specific human milk oligosaccharides influenced the
development of intestinal microbiota in mice as indicated by
changes in the abundance of Barnesiella. Although Barnesiella
bacteria belong to the major bacterial genera in mice, their
representation in human microbiota is minor(30,44) and changes
in the composition of Barnesiella have not been reported yet
to be associated with resistance to gastrointestinal disorders in
humans. Nevertheless, supplementation of 2-FL might be of
interest in children whose mothers lack 2-FL in breast milk.
Approximately 20% of Caucasians have a genetic inability to
express a(1,2)-fucosyltransferase activity. In women, this results
in the lack of a(1,2)-linked fucose in milk oligosaccharides,
thereby to 2-FL deficiency in milk(10,45). As a(1,2)-fucosylated
oligosaccharides inhibit the attachment of several enteric
pathogens, the absence of these glycans is associated with
different infectious diseases(14,46–48). Current research focuses
on the synthesis of fucosyllactose by Escherichia coli (49) or
with the help of bacterial enzymes(50,51) for the production of
food additives. To prevent disadvantages in children of the
so-called non-secretors, especially in the context of necrotising
enterocolitis, the supplementation of 2-FL might become a
possible treatment option.
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